WASHINGTON — The Trump administration wants pharmaceutical companies to include the list price of drugs in television advertisements.

The Department of Health and Human Services released a proposed regulation Monday afternoon that, if finalized, would require companies that sell drugs covered by Medicare or Medicaid to put a standard price in their ads, if the price is larger than $35 per month.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • It would be far more useful in driving consumer costs down if the price disclosed in drug advertising were the negotiated price paid by Medicare or Medicaid. Then employees would ask their HR team or their insurer “Why am I paying three times as much?”

    • Actually Medicare is forbidden by law from negotiating drug prices. Medicaid doesn’t negotiate either, but they are entitled to the “best price” offered to any other US customer.

  • I’m down with it — as long as they’re required to run back-to-back with an ad from all the major PBMs, listing the rebates they take off the list price…and how much of that they pocket.

  • Advertising drug prices won’t do anything to lower drug prices !!!! What doesn’t Mr. Azar and the president get ? Unless there is total transparency with ALL aspects of what the PBM’s do , NOTHING will change !!!!!! This is the reason for,and will always be the reason for high drug prices !

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy